In Brief - Vertex Pharmaceuticals (VRTX) Stock

Shares of Health Care sector company Vertex Pharmaceuticals moved -0.1% today, and are now trading at a price of $349.07. The large-cap stock's daily volume was 584,469 compared to its average volume of 1,079,570. The S&P 500 index returned a 0.0% performance.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). The company is based in Boston and has 4,800 full time employees. Its market capitalization is $89,950,412,800.

25 analysts are following Vertex Pharmaceuticals and have set target prices ranging from $298.76 to $419.18 per share. On average, they have given the company a rating of buy. At today's prices, VRTX is trading -5.07% away from its average analyst target price of $367.7 per share.

Over the last year, VRTX's share price has increased by 13.0%, which represents a difference of -2.0% when compared to the S&P 500. The stock's 52 week high is $387.42 per share whereas its 52 week low is $282.21. With average free cash flows of $2.65 Billion that have been growing at an average rate of 22.0% over the last 6 years, Vertex Pharmaceuticals is in a position to continue its strong stock performance trend.

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cash Flow ($ k) YoY Growth (%)
2023 4,068,200 189,500 3,878,700 -1.18
2022 4,129,900 204,700 3,925,200 62.97
2021 2,643,500 235,000 2,408,500 -19.55
2020 3,253,500 259,800 2,993,700 100.39
2019 1,569,300 75,400 1,493,900 27.16
2018 1,270,286 95,449 1,174,837
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.